Low-dose lithium demonstrates potential therapeutic benefit for mild cognitive impairment, suggesting a possible off-label or repurposing opportunity for dementia-related behavioral symptoms.
Compass Pathways plans to file for FDA approval of a psilocybin-based treatment for depression following successful Phase 3 trial results, representing a significant development in psychedelic psychiatry.
A proof-of-concept RCT shows that a single dose of the anti-inflammatory agent tocilizumab cleared inflammation in depressed patients, though its clinical efficacy on depressive symptoms requires further investigation.
A dual-modal diagnostic model combining serum metabolomics and clinical risk factors demonstrates high accuracy for identifying treatment-resistant depression, offering insights into metabolic mechanisms rather than immediate prescribing changes.
Preclinical rat data demonstrate that an intranasal clozapine sol-gel formulation achieves antipsychotic efficacy at 3.5% of the oral dose with reduced peripheral exposure and metabolic side effects, suggesting a promising delivery method for further clinical investigation.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 16 – May 21)
- Consider a sequential regimen of ketamine followed by low-dose buprenorphine to extend the duration of anti-suicidal effects beyond the typical one-week window.
- Monitor hepatic function closely in patients prescribed psychotropic medications, as antidepressant-induced liver injury remains a significant clinical risk.
- Utilize tocilizumab as a potential repurposing option for treatment-resistant depression, particularly in patients with evidence of systemic inflammation.
- Advise patients that switching to salt-nicotine e-cigarettes can triple their odds of successful smoking cessation compared to traditional methods.
- Investigate mirtazapine as a repurposing candidate for methamphetamine use disorder, leveraging its existing antidepressant profile for substance use treatment.
- Recognize that preclinical data suggests KarXT's mechanism involves gut microbiota modulation, which may help explain its gastrointestinal side effect profile.
- Consider low-dose lithium as a potential off-label therapeutic option for managing behavioral symptoms associated with mild cognitive impairment.
- Review seasonal prescribing patterns for hypnotics and sedatives, noting that rates peak in winter and decline with increased daylight exposure.
- Exercise caution with psilocybin administration due to rare but serious adverse events such as sudden loss of consciousness.
- Evaluate the olanzapine-samidorphan combination for schizophrenia patients who require antipsychotic efficacy but struggle with weight gain or metabolic side effects.
Diagnosis & Treatment 2
The anti-inflammatory drug tocilizumab, approved for arthritis, has been shown to induce remission in patients with treatment-resistant depression, suggesting a potential repurposing opportunity for this psychopharmacologic indication.
This retrospective study identifies significant seasonal and gender-specific variations in primary care prescribing of hypnotic and sedative medications, with rates peaking in winter and declining with increased daylight exposure.
Drug Development 2
Jupiter Neurosciences stock rises following a licensing deal for MDMA therapy, highlighting ongoing commercial developments in psychedelic psychiatry.
The article discusses the potential of CTX-1301, a novel therapeutic candidate, for the treatment of ADHD, representing ongoing drug development in psychiatric pharmacology.
Podcast Summary 1
This podcast summary covers the recognition and treatment of bipolar disorder with mixed features, featuring expert commentary from Roger McIntyre, MD.
Mechanism of Action 2
Research indicates that a single dose of psilocybin may provide rapid relief from depression symptoms within days, highlighting its potential as a fast-acting therapeutic agent for major depressive disorder.
Preclinical data suggest KarXT (xanomeline-trospium) reverses cognitive deficits in a schizophrenia mouse model via gut microbiota modulation, offering potential insights into its mechanism and gastrointestinal side effects.
Clinical Pearl 2
A pilot randomized controlled trial published in JAMA Psychiatry suggests that an anti-inflammatory immunotherapy may be a promising treatment option for difficult-to-treat depression.
This review addresses the risk of antidepressant-induced liver injury, providing clinicians with essential information for monitoring and managing hepatic adverse effects in patients prescribed psychotropic medications.
Policy & Regulation 1
Vertical Pharmaceuticals partners with Medfinder to help patients locate Relexxii (methylphenidate) during ongoing ADHD medication shortages.
Journal Article 1
This study analyzes psychotropic dispensing patterns in Portugal during and after the COVID-19 pandemic, providing epidemiological data on prescribing trends rather than direct clinical pharmacology guidance.
Substance Use 3
A randomized trial indicates that switching to salt-nicotine e-cigarettes triples smoking cessation odds, offering a relevant pharmacotherapy option for substance use disorder treatment.
Mirtazapine is being investigated as a potential treatment for methamphetamine use disorder, highlighting a repurposing opportunity for an existing antidepressant.
Case report of sudden loss of consciousness following psilocybin ingestion, highlighting a rare but serious adverse event associated with psychedelic use.